Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03065062
Title Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute
Indications

head and neck squamous cell carcinoma

pancreatic cancer

lung squamous cell carcinoma

endometrial cancer

Advanced Solid Tumor

Therapies

Gedatolisib + Palbociclib

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Massachusetts General Hospital Not yet recruiting Boston Massachusetts 02114 United States Details
Beth Israel Deaconess Medical Center Not yet recruiting Boston Massachusetts 02115 United States Details
Dana Farber Cancer Institute Recruiting Boston Massachusetts 02115 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field